Remove 2007 Remove Testimonials Remove Trials
article thumbnail

Let's Quit Sugar With Audiobook – Let's Quit Sugar

The Pharma Data

Testimonials are not necessarily representative of all of those who will use our products. Some of our testimonials are provided by customers who have received promotional offers in exchange for their participation. The testimonials displayed are given verbatim except for correction of grammatical or typing errors. 2012.11.002.

Disease 52
article thumbnail

No Expert Do-Overs

Drug & Device Law

Plaintiffs will not be heard to argue that they “could have shored up their cases by other means had they known their expert testimony would be found inadmissible.” His inability to produce admissible expert testimony is due to his own actions, namely the failure of his proposed experts to test their alternatives. Fru-Con Inc. ,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Malarkey ? The Ten Worst Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

We’ve been diligently preparing bottom ten annual lists since 2007, even though it’s distasteful, because if we don’t do it nobody else is likely to, and these abominable decisions deserve to be called out for what they are. While we know that a late-breaking holiday horror, such as T.H.

article thumbnail

Taxotere Timing Troubles Persistently Plague Plaintiffs

Drug & Device Law

She completed her therapy in 2007, more than ten years before she filed suit – that suit having been solicited by a p-side lawyer. Her “injury” thus existed as of December 30, 2007, six months after her treatment was completed. Plaintiff Adams was typical. This wasn’t a close case. at *34-35.

article thumbnail

Guest Post – More on Expert Gatekeeping in West Virginia

Drug & Device Law

702 was (at the time – more on this below) identical to the Federal Rule, the Court stated “we believe that Daubert is directed at situations where the scientific or technical basis for the expert testimony cannot be judicially noticed and a hearing must be held to determine its reliability. 2007) (citation omitted). 2d 864, 880 (W.

article thumbnail

50-State Survey of State Court Decisions Supporting Expert-Related Judicial Gatekeeping

Drug & Device Law

We think that they can, and for a state (like Pennsylvania and a number of others) that still follows the “ Frye ” standard looking to the “general acceptance” of expert testimony as the touchstone to admissibility, a Rule 702 state-law equivalent might look something like this: Rule 702. E.g. , Walsh v. BASF Corp. , 3d 446, 461 (Pa.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

14, 2015) (claimed alternative could not be considered for plaintiffs who “had their surgeries prior to the commercial availability of” the claimed alternative because it “was not approved by the Food and Drug Administration until June 2007 and was not commercially available until late” that year). Ethicon, Inc. , 3d , 2022 WL 6225596 (S.D.

FDA 59